Table 1.
Baseline patient characteristics
| Denosumab (SC Q6M) (n = 224) | Ibandronate (oral QM) (n = 217) | |
|---|---|---|
| Age, years | ||
| Mean (SD) | 63.4 (7.74) | 64.4 (8.27) |
| Age at menopause onset, years | ||
| Mean (SD) | 47.8 (4.36) | 48.9 (3.65) |
| Previous fragility fracture | ||
| n (%) | 57 (25.4) | 38 (17.5) |
| Location of previous fragility fracture, n (%) | ||
| N | 57 | 38 |
| Hip | 7 (12.3) | 0 (0) |
| Vertebrae | 42 (73.7) | 31 (81.6) |
| Other | 9 (15.8) | 7 (18.4) |
| Previous PMO therapy | ||
| n (%) | 44 (19.6) | 26 (12.0) |
| Calcium/vitamin D supplements, n (%) | ||
| Calcium plus vitamin D | 116 (51.8) | 115 (53.0) |
| Calcium or vitamin D | 135 (60.3) | 135 (62.2) |
| None | 89 (39.7) | 82 (37.8) |
| Systemic glucocorticoid use, n (%) | ||
| Yes | 11 (4.9) | 5 (2.3) |
| No | 213 (95.1) | 157 (72.4) |
| NA | – | 55 (25.4) |
| Secondary osteoporosis | ||
| n (%) | 13 (5.8) | 9 (4.2) |
NA not applicable, PMO postmenopausal osteoporosis, QM every month, Q6M every 6 months, SC subcutaneous, SD standard deviation